Show simple item record

Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

dc.contributor.authorGurel, Selim
dc.contributor.authorErsoz, Galip
dc.contributor.authorOzenirler, Seren
dc.contributor.authorKalayci, Cem
dc.contributor.authorPoturoglu, Sule
dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorOkten, Atilla
dc.contributor.authorCakaloglu, Yilmaz
dc.contributor.authorOguz, Dilek
dc.contributor.authorGur, Gurden
dc.contributor.authorTankurt, Ethem
dc.date.accessioned2021-03-03T13:39:44Z
dc.date.available2021-03-03T13:39:44Z
dc.date.issued2007
dc.identifier.citationKaymakoglu S., Oguz D., Gur G., Gurel S., Tankurt E., Ersoz G., Ozenirler S., Kalayci C., Poturoglu S., Cakaloglu Y., et al., "Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, cilt.51, sa.8, ss.3020-3022, 2007
dc.identifier.issn0066-4804
dc.identifier.othervv_1032021
dc.identifier.otherav_3552f795-5156-4304-88aa-f69628549555
dc.identifier.urihttp://hdl.handle.net/20.500.12627/40045
dc.identifier.urihttps://doi.org/10.1128/aac.00088-07
dc.description.abstractForty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of < 400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.
dc.language.isoeng
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.titlePegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B
dc.typeMakale
dc.relation.journalANTIMICROBIAL AGENTS AND CHEMOTHERAPY
dc.contributor.department, ,
dc.identifier.volume51
dc.identifier.issue8
dc.identifier.startpage3020
dc.identifier.endpage3022
dc.contributor.firstauthorID184014


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record